
A high backtest Sharpe ratio proves little: what real validation requires
Reported Sharpe ratios inflate with every unreported trial, and the corrections that account for this are arithmetic, not opinion.

Reported Sharpe ratios inflate with every unreported trial, and the corrections that account for this are arithmetic, not opinion.

Out-of-sample scoring is the only published test that approximates live trading, and most papers still manage to overstate it.

A diagnostic built to answer one question a good Sharpe ratio can't: how much of a backtested strategy's performance is signal, and how much is the number of…

AI-driven trading and forecasting tools are often sold on the strength of impressive backtested results. Here is the mechanism by which those results can be…

Multiple testing turns luck into apparent skill. What the correction procedures control, the hurdles the replication literature settled on, and what a corrected…

Federal regulators rewrote model risk management guidance in April 2026, keeping the same validation core built around conceptual soundness and outcomes…

Ten trials are enough to yield an in-sample Sharpe ratio of 1.57 from strategies with zero expected out-of-sample performance. What validation, multiple-testing…

The SEC's first AI-washing settlements penalized false marketing about artificial intelligence, not a model's forecasting accuracy — a distinction that matters…